Skip to content
Pharma Observatory a Scientist.com platform

Organization (Hospital)

Wuxi People's Hospital

ClinicalTrials.gov lists Wuxi People's Hospital as lead sponsor of 16 trials.

CN Hospital
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

9 0 2011 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 1 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 0 in 2026 and about 2 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. The 2026 forecast is below the 1 already registered with a 2026 start date: at the cutoff, 1 trials were already registered to start in October to December, more than the method's monthly average allows for, and the method does not use those planned starts.

This page covers Wuxi People's Hospital: 16 lead-sponsored trials and 1 legal-entity registration.

Get the Wuxi People's Hospital report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (43)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Diabetes Mellitus 3
Stomach Neoplasms 3
Diabetes Mellitus, Type 2 2
Glucose Intolerance 2
Hyperglycemia 2

Trials by start year as sponsor or collaborator (13)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 1
2025 2
2024 4
2023 8
2022 9
2021 8
2020 2
2018 1
2017 3
2016 3

Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Journals published in (84)

Shown in this order: most published in first.

Journals published in
Journal Publications
Clinical nutrition (Edinburgh, Scotland) 8
Frontiers in oncology 4
Lancet (London, England) 4
The New England journal of medicine 4
Annals of surgical oncology 3

US granted patents (1)

Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.

US granted patents
US patents granted Granted in the last 5 years Most recent grant
3 1 2023-11-28

Organization relationships (20)

Shown in this order: most evidence first.

Organization relationships
Related organization Relationship Evidence
Zhongda Hospital Co sponsors trial with 2
Huizhou Third People's Hospital, Guangzhou Medical University Co sponsors trial with 2
Shanghai Zhongshan Hospital Co sponsors trial with 2
The First Hospital of Jilin University Co sponsors trial with 2
Affiliated Hospital of Guangdong Medical University Co sponsors trial with 2

Latest dated events (49)

Shown in this order: newest first.

Latest dated events
Date Event Source
2026-10-08 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2025-09-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2025-03-03 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2024-12-30 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2024-05-07 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Biomarker capability evidence (30)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ALB Trial collaborator Named in trial inclusion criteria
AR Trial collaborator Named in trial inclusion criteria
BTK Trial collaborator Named in trial inclusion criteria
CD33 Trial sponsor Named in trial inclusion criteria
CLEC12A Trial sponsor Named in trial inclusion criteria

Biomarkers this organization publishes on (35)

Shown in this order: most publications first.

Biomarkers this organization publishes on
Biomarker Publications
CRP 3
MPL 3
ALB 2
CSF3 2
EPO 2

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, approved assets, sponsor delivery record, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.